Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms AFFIRM
  • Sponsors Biogen Idec
  • Most Recent Events

    • 01 Oct 2023 Results from pooled analysis from NCT00027300, NCT00030966 associations association of age and inflammatory disease activity published in the Journal of Neurology, Neurosurgery and Psychiatry.
    • 01 Dec 2022 Results assessing the sensitivity and clinical meaningfulness of ODRS using natalizumab Phase 3 data sets -AFFIRM in relapsing-remitting MS and ASCEND in secondary progressive MS, published in the Multiple Sclerosis Journal
    • 26 Feb 2022 Results of an analysis assessed the gray and thalamic atrophy in patients with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab or placebo and to estimate the treatment effect of natalizumabpresented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top